Celldex Therapeutics, Inc.
CLDX · In Vitro and in Vivo Diagnostic Substances
Latest available SEC filing: SCHEDULE 13G ·
Latest disclosures
-
Form SCHEDULE 13G
SEC filing · Filed
-
Latest financial period: Q2 2026
Financial facts · Filed
-
Form 10-Q
SEC filing · Filed
-
Lawver Teri L: Form 4
Insider disclosure · Filed · Report period 25 Jun 2026
-
Form 4
SEC filing · Filed
-
Form 4
SEC filing · Filed
-
Form 4
SEC filing · Filed
-
Form 4
SEC filing · Filed
Institutional holders by security
Choose a share class to see reported 13F positions and quarterly changes. Different securities have separate holder histories.
Company details and SEC sources
CIK 0000744218 · SEC filing index. Filing dates describe disclosures, not live market data.
- Listed symbols
- CLDX on Nasdaq
- SEC industry group
- In Vitro and in Vivo Diagnostic Substances (Office of Life Sciences)
- Business address
- 53 Frontage Road, Suite 220, Hampton, NJ, 08827
- Incorporated in
- DE
- Fiscal year end
- 31 December
- Former names on EDGAR
- AVANT IMMUNOTHERAPEUTICS INC (to 29 Sep 2008), T CELL SCIENCES INC (to 21 Aug 1998)
At a glance
Names, identifiers, and filing context for this profile.
2 identity fields